| 摘要 |
PURPOSE: A maleic acid trimebutine sustained release tablet is provided to ensure improved release rate and easy administration and to reduce headache, dizziness, and sleepiness. CONSTITUTION: A trimebutine sustained release tablet comprises: 30-60 weight% of trimebutine, 4-10 weight% of hydroxypropylmethylcellulose, 20-50 weight% of excipient of lactose, mannitol, glucose, sorbitol, dextrin or sucrose, 3-10 weight% of povidone and 3-7 weight% of lubricant. The trimebutine is maleic acid trimebutine. A method for manufacturing the trimebutine sustained release tablet comprises: a step of mixing 30-60 weight% of trimebutine, 4-10 weight% of hydroxypropylmethylcellulose, and 20-50 weight% of excipient; a step of granulating and drying; and a step of adding lubricant and tableting.
|
